Open AccessJournal Article
Binding of taxol to human plasma, albumin and alpha 1-acid glycoprotein.
Reads0
Chats0
TLDR
The protein binding ofTaxol was found to dramatically decrease the red blood cell uptake of taxol, indicating nonspecific hydrophobic binding.Abstract:
The binding of taxol to human plasma and to individual plasma proteins was studied by equilibrium dialysis. Taxol was found to bind extensively (about 95%) without a significant difference between healthy volunteers and cancer patients. At clinically relevant concentrations (0.1-6 microM), the binding was found to be concentration independent, indicating nonspecific hydrophobic binding. Human serum albumin and alpha 1-acid glycoprotein were found to contribute about equally to the binding, with a minor contribution from lipoproteins. None of the drugs commonly coadministered with taxol (dexamethasone, diphenhydramine, ranitidine, doxorubicin, 5-fluorouracil and cisplatin) altered the binding of taxol significantly. The protein binding of taxol was found to dramatically decrease the red blood cell uptake of taxol.read more
Citations
More filters
Journal ArticleDOI
Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer
William J. Gradishar,Sergei Tjulandin,Neville Davidson,Heather S. Shaw,Neil Desai,P. Bhar,Michael M. Hawkins,Joyce O'Shaughnessy +7 more
TL;DR: The improved therapeutic index and elimination of corticosteroid premedication required for solvent-based taxanes make the novel albumin-bound paclitaxel ABI-007 an important advance in the treatment of MBC.
Journal ArticleDOI
Paclitaxel and its formulations.
TL;DR: There is a need for the development of alternate formulation of paclitaxel having good aqueous solubility and at the same time free of any side effects.
Journal ArticleDOI
Model of Chemotherapy-Induced Myelosuppression With Parameter Consistency Across Drugs
TL;DR: A semimechanistic pharmacokinetic-pharmacodynamic model describing chemotherapy-induced myelosuppression through drug-specific parameters and system-related parameters, which are common to all drugs, is proposed and can be a useful tool in the development of anticancer drugs and therapies.
Journal ArticleDOI
Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer
Caroline M. Spencer,Diana Faulds +1 more
TL;DR: Paclitaxel was successfully combined with cisplatin, carboplatin and/or etoposide in patients with NSCLC, SCLC or advanced squamous cell carcinoma of the head and neck and was more effective than mitomycin in 50 patients with previously untreated breast cancer.
Patent
Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
Neil P. Desai,Chunlin Tao,Andrew Yang,Leslie Louie,Tianli Zheng,Zhiwen Yao,Patrick Soon-Shiong,Shlomo Magdassi +7 more
TL;DR: In this article, the authors provided compositions and methods useful for the in vivo delivery of substantially water insoluble pharmacologically active agents (such as the anticancer drug paclitaxel) in the form of suspended particles coated with protein (which acts as stabilizing agent).